0
February 12, 1982, Vol 247, No. 6 >
ARTICLE | February 12, 1982

Metabolites and Analogues of Vitamin D: Title and subTitle BreakWhich for What? FREE

Mark R. Haussler, PhD; Peter E. Cordy, MD
[+] Author Affiliations

Reprint requests to Department of Biochemistry, University of Arizona Health Sciences Center, Tucson, AZ 85724 (Dr Haussler).


JAMA. 1982;247(6):841-844. doi:10.1001/jama.1982.03320310085047
Text Size: A A A
Published online
Article
References

The discovery and chemical synthesis of several biologically active derivatives of vitamin D have increased the number of compounds available for the treatment of disorders of bone and mineral metabolism. Calcitriol is the most active natural metabolite of vitamin D, but analogues like dihydrotachysterol and calcifediol also are safe and effective therapeutic agents. These vitamin D congeners have been useful in the treatment of renal osteodystrophy, hypoparathyroidism, and other disorders refractory to vitamin D therapy. Certain analogues may offer distinct advantages over vitamin D, depending on the nature of the defect. All vitamin D derivatives should be used cautiously, with frequent monitoring of serum calcium levels to prevent toxic reactions.

(JAMA 1982;247:841-844)

REFERENCES

1 +
Haussler MR, McCain TA:  Basic and clinical concepts related to vitamin D metabolism and action . N Engl J Med 1977;;297:974-983, 1041-1050.
2 +
Zerwekh JE, Brumbaugh PF, Haussler DH, et al:  1α-Hydroxyvitamin D3: An analog of vitamin D which apparently acts by metabolism to 1α,25-dihydroxyvitamin D3 . Biochemistry 1974;;13:4097-4102.
3 +
Hallick RB, DeLuca HF:  Metabolites of dihydrotachysterol in target tissues . J Biol Chem 1972;;247:91-97.
4 +
Procsal DA, Okamura WH, Norman AW:  Structural requirements for the interaction of 1α,25(OH)2vitamin D, with its chick intestinal receptor system . J Biol Chem 1975;;250:8382-8388.
5 +
Holtz F, Schreiber E:  Einige veitere physiologische erfahrungen uberdas bestrahlte ergosterin und seine umwandlungsprodukte . Z Physiol Chem 1930;;191:1-22.
6 +
Harrison HE, Lifshitz F, Blizzard RM:  Comparison between crystalline dihydrotachysterol and calciferol in patients requiring pharmacologic vitamin D therapy . N Engl J Med 1967;;276:894-900.
7 +
Dent CE, Harper CM, Philpot GR:  The treatment of renal glomerular osteodystrophy . Q J Med 1961;;30:1-31.
8 +
Kaye M, Chatterjee G, Cohen GF, et al:  Arrest of hyperparathyroid bone disease with dihydrotachysterol in patients undergoing chronic hemodialysis . Ann Intern Med 1970;; 73:225-233.
9 +
Cordy PE, Mills DM:  The early detection and treatment of renal osteodystrophy . Mineral Electrolyte Metab 1981;;5:311-320.
10 +
Russell RGG, Smith R, Walton RJ, et al:  1,25-Dihydroxycholecalciferol and 1α-hydroxycholecalciferol in hypoparathyroidism . Lancet 1974;;2:14-17.
11 +
Drezner MK, Lyles KW, Haussler MR, et al:  Evaluation of a role for 1,25-dihydroxyvitamin D, in the pathogenesis and treatment of X-linked hypophosphatemic rickets and osteomalacia . J Clin Invest 1980;;66:1020-1032.
12 +
Frazer D, Kooh SW, Kind HP, et al:  Pathogenesis of hereditary vitamin D dependent rickets . N Engl J Med 1973;;289:817-822.
13 +
Coburn JW, Brickman AS, Sherwood DJ, et al:  Use of 1,25(OH)vitamin D, to separate types of renal osteodystrophy . Proc Eur Dial Transplant Assoc 1977;;14:442-450.
14 +
Chesney RW, Moorthy AV, Eisman JA, et al:  Increased growth after long-term oral 1α,25-vitamin D, in childhood renal osteodystrophy . N Engl J Med 1978;;298:238-242.
15 +
Malluche HH, Goldstein DA, Massry SG:  Management of renal osteodystrophy with 1,25(OH)2D3: II. Effects on histopathology of bone: Evidence for healing of osteomalacia . Mineral Electrolyte Metab 1979;;2:48-55.
16 +
Brickman AS, Coburn JW, Friedman GR, et al:  Comparison of effects of 1α-hydroxyvitamin D3 and 1,25-dihydroxy-vitamin D, in man . J Clin Invest 1976;;57:1540-1547.
17 +
Rasmussen H, Anast C, Parks J, et al:  1α(OH)D3 in treatment of hypophosphatemic rickets , abstracted. Clin Res 1976;;24:486.
18 +
Davie WJ, Chalmers TM, Hunter JO, et al:  1-Alpha-cholecalciferol in chronic renal failure . Ann Intern Med 1976;;84:281-285.
19 +
Rutherford WE, Blondin J, Hruska K, et al:  Effect of 25-hydroxycholecalciferol on calcium absorption in chronic renal disease . Kidney Int 1975;;8:320-324.
20 +
Soberon LM, Brickman AS, Coburn JW:  Comparison of effects of 250HD3 and dihydrotachysterol (DHT) on Ca absorption (ICA) in uremia , abstracted. Kidney Int 1979;;16:184.
21 +
Recker R, Shoenfield P, Letteri J, et al:  The efficacy of calcifediol in renal osteodystrophy . Arch Intern Med 1978;;138:857-863.
22 +
Fournier A, Bordier P, Gueris J, et al:  Comparison of 1α-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy . Kidney Int 1979;;15:196-204.
23 +
Endo H, Kiyoki M, Kawashima K, et al:  Vitamin D, metabolites and PTH synergistically stimulate bone formation of chick embryonic femur in vitro . Nature 1980;;286:262-264.
24 +
Davies M, Mawer EB, Adams PH:  Vitamin D metabolism and the response to 1,25-dihydroxycholecalciferol in osteoporosis . J Clin Endocrinol Metab 1977;;45:199-208.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

1 +
Haussler MR, McCain TA:  Basic and clinical concepts related to vitamin D metabolism and action . N Engl J Med 1977;;297:974-983, 1041-1050.
2 +
Zerwekh JE, Brumbaugh PF, Haussler DH, et al:  1α-Hydroxyvitamin D3: An analog of vitamin D which apparently acts by metabolism to 1α,25-dihydroxyvitamin D3 . Biochemistry 1974;;13:4097-4102.
3 +
Hallick RB, DeLuca HF:  Metabolites of dihydrotachysterol in target tissues . J Biol Chem 1972;;247:91-97.
4 +
Procsal DA, Okamura WH, Norman AW:  Structural requirements for the interaction of 1α,25(OH)2vitamin D, with its chick intestinal receptor system . J Biol Chem 1975;;250:8382-8388.
5 +
Holtz F, Schreiber E:  Einige veitere physiologische erfahrungen uberdas bestrahlte ergosterin und seine umwandlungsprodukte . Z Physiol Chem 1930;;191:1-22.
6 +
Harrison HE, Lifshitz F, Blizzard RM:  Comparison between crystalline dihydrotachysterol and calciferol in patients requiring pharmacologic vitamin D therapy . N Engl J Med 1967;;276:894-900.
7 +
Dent CE, Harper CM, Philpot GR:  The treatment of renal glomerular osteodystrophy . Q J Med 1961;;30:1-31.
8 +
Kaye M, Chatterjee G, Cohen GF, et al:  Arrest of hyperparathyroid bone disease with dihydrotachysterol in patients undergoing chronic hemodialysis . Ann Intern Med 1970;; 73:225-233.
9 +
Cordy PE, Mills DM:  The early detection and treatment of renal osteodystrophy . Mineral Electrolyte Metab 1981;;5:311-320.
10 +
Russell RGG, Smith R, Walton RJ, et al:  1,25-Dihydroxycholecalciferol and 1α-hydroxycholecalciferol in hypoparathyroidism . Lancet 1974;;2:14-17.
11 +
Drezner MK, Lyles KW, Haussler MR, et al:  Evaluation of a role for 1,25-dihydroxyvitamin D, in the pathogenesis and treatment of X-linked hypophosphatemic rickets and osteomalacia . J Clin Invest 1980;;66:1020-1032.
12 +
Frazer D, Kooh SW, Kind HP, et al:  Pathogenesis of hereditary vitamin D dependent rickets . N Engl J Med 1973;;289:817-822.
13 +
Coburn JW, Brickman AS, Sherwood DJ, et al:  Use of 1,25(OH)vitamin D, to separate types of renal osteodystrophy . Proc Eur Dial Transplant Assoc 1977;;14:442-450.
14 +
Chesney RW, Moorthy AV, Eisman JA, et al:  Increased growth after long-term oral 1α,25-vitamin D, in childhood renal osteodystrophy . N Engl J Med 1978;;298:238-242.
15 +
Malluche HH, Goldstein DA, Massry SG:  Management of renal osteodystrophy with 1,25(OH)2D3: II. Effects on histopathology of bone: Evidence for healing of osteomalacia . Mineral Electrolyte Metab 1979;;2:48-55.
16 +
Brickman AS, Coburn JW, Friedman GR, et al:  Comparison of effects of 1α-hydroxyvitamin D3 and 1,25-dihydroxy-vitamin D, in man . J Clin Invest 1976;;57:1540-1547.
17 +
Rasmussen H, Anast C, Parks J, et al:  1α(OH)D3 in treatment of hypophosphatemic rickets , abstracted. Clin Res 1976;;24:486.
18 +
Davie WJ, Chalmers TM, Hunter JO, et al:  1-Alpha-cholecalciferol in chronic renal failure . Ann Intern Med 1976;;84:281-285.
19 +
Rutherford WE, Blondin J, Hruska K, et al:  Effect of 25-hydroxycholecalciferol on calcium absorption in chronic renal disease . Kidney Int 1975;;8:320-324.
20 +
Soberon LM, Brickman AS, Coburn JW:  Comparison of effects of 250HD3 and dihydrotachysterol (DHT) on Ca absorption (ICA) in uremia , abstracted. Kidney Int 1979;;16:184.
21 +
Recker R, Shoenfield P, Letteri J, et al:  The efficacy of calcifediol in renal osteodystrophy . Arch Intern Med 1978;;138:857-863.
22 +
Fournier A, Bordier P, Gueris J, et al:  Comparison of 1α-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy . Kidney Int 1979;;15:196-204.
23 +
Endo H, Kiyoki M, Kawashima K, et al:  Vitamin D, metabolites and PTH synergistically stimulate bone formation of chick embryonic femur in vitro . Nature 1980;;286:262-264.
24 +
Davies M, Mawer EB, Adams PH:  Vitamin D metabolism and the response to 1,25-dihydroxycholecalciferol in osteoporosis . J Clin Endocrinol Metab 1977;;45:199-208.

Letters

Submit a Letter
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general journals
BMJ 2010;341:c5893-c1494.
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

© 2012 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems